Clinical trials
Completed Phase 2 trials in India
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
392 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 8 |
| 2004 | 11 |
| 2005 | 23 |
| 2006 | 23 |
| 2007 | 41 |
| 2008 | 43 |
| 2009 | 36 |
| 2010 | 31 |
| 2011 | 30 |
| 2012 | 19 |
| 2013 | 14 |
| 2014 | 6 |
| 2015 | 6 |
| 2016 | 5 |
| 2017 | 10 |
| 2018 | 9 |
| 2019 | 11 |
| 2020 | 17 |
| 2021 | 12 |
| 2022 | 15 |
| 2023 | 12 |
| 2024 | 6 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 392 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GlaxoSmithKline | 24 |
| Novartis Pharmaceuticals | 24 |
| Pfizer | 19 |
| Eli Lilly and Company | 13 |
| Sanofi | 10 |
| Novo Nordisk A/S | 9 |
| Post Graduate Institute of Medical Education and Research, Chandigarh | 9 |
| AstraZeneca | 8 |
| Boehringer Ingelheim | 6 |
| Government Dental College and Research Institute, Bangalore | 6 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 29 |
| Diabetes Mellitus, Type 2 | 22 |
| Carcinoma, Non-Small-Cell Lung | 14 |
| Neoplasms | 13 |
| Arthritis, Rheumatoid | 11 |
| Asthma | 11 |
| COVID-19 | 10 |
| Diabetes Mellitus | 9 |
| Schizophrenia | 9 |
| Lupus Erythematosus, Systemic | 8 |
Trials
Showing 1 to 25 of 392. Each trial links to its page on Pharma Observatory.
292 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.